ArticleDrugs in R&D2015

Early Benefit Assessments in Oncology in Germany: How Can a Clinically Relevant Endpoint Not Be Relevant to Patients?

Jörg Ruof et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.